165668-32-6Relevant articles and documents
LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE
-
, (2008/06/13)
A lymphocyte activation inhibitor and a therapeutic agent for an autoimmune disease, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): wherein the ring A represents a monocyclic or bicyclic aromatic ring which may be substituted, the ring B represents a 6-membered unsaturated hydrocarbon ring or a 6-membered unsaturated heterocyclic ring containing one nitrogen atom as a heteroatom, each of which may be substituted, the ring C represents a 5-membered heterocyclic ring containing one or two nitrogen atoms, which may be substituted, W represents a single bond or -CH=CH-, X represents -N(R1)- or an oxygen atom, Y represents a carbon atom or a nitrogen atom, Z represents -N(R2)- or a nitrogen atom, and R1 and R2 may be identical or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, or a hydrate thereof.
A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors
Owa, Takashi,Okauchi, Tatsuo,Yoshimatsu, Kentaro,Sugi, Naoko Hata,Ozawa, Yoichi,Nagasu, Takeshi,Koyanagi, Nozomu,Okabe, Tadashi,Kitoh, Kyosuke,Yoshino, Hiroshi
, p. 1223 - 1226 (2007/10/03)
A series of compounds containing an N-(7-indolyl)benzenesulfonamide pharmacophore was synthesized and evaluated as a potential antitumor agent. Cell cycle analysis with P388 murine leukemia cells revealed that there were two different classes of potent cell cycle inhibitors; one disrupted mitosis and the other caused G1 accumulation. Herein described is the SAR summary of the substituent patterns on this pharmacophore template. (C) 2000 Elsevier Science Ltd. All rights reserved.